A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

This new treatment could help bring relief for millions of Americans struggling with depression. The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.